CORE-014: COMPARATIVE PATHOLOGY AND MOUSE PHENOTYPING (CPMPSR) PROJECT SUMMARY / ABSTRACT The Comparative Pathology and Mouse Phenotyping Shared Resource (CPMPSR) provides expert, readily available and affordable pathology support to investigators utilizing animal models to study human cancer. The use of animal models in cancer research, particularly inbred and genetically engineered mice, has increased exponentially over the past several years due to technological advances and completion of the sequencing of the human and mouse genomes. Virtually every OSUCCC member utilizing experimental animal models will need at least some of the services provided by the CPMPSR.
The Specific Aims of the CPMPSR are: 1) to provide support for preclinical efficacy and toxicity studies utilizing a variety of animal species; 2) to provide consultative services to OSUCCC investigators for optimal experimental design, sample submission and data analysis, recommendations as needed for various ancillary tests, referrals to other OSUCCC shared resources and cores, and referrals to investigators' laboratories with specific expertise (e.g., more specialized clinical pathology testing, electron microscopy, imaging, behavioral and physiological testing); and, 3) to provide consultations to investigators at the time of grant applications and manuscript submissions by providing details about methods and pathologic findings. The services provided by CPMPSR, directed by Dr. Krista La Perle include macroscopic and microscopic tissue evaluations, clinical pathology testing, comprehensive histology and immunohistochemistry, microscopic slide imaging and quantitative analysis. The CPMPSR also provides comprehensive phenotypic characterization of genetically-engineered mice, including detailed characterization of embryos. Radiography is performed by the CPMPSR to enhance morphologic evaluations on post-mortem specimens. The CPMPSR regularly interacts with other OSUCCC shared resources such as the Microscopy Shared Resource and Biomedical Informatics Shared Resource. Over the past grant period, the CPMPSR was utilized by all five OSUCCC Research Programs studying carcinogenesis and using preclinical models for drug development. CPMPSR provided services to 117 OSUCCC members, and these members accounted for 53% of usage. The CPMPSR has also supported the research for 93 cancer publications, of which 11 were published in journals with an impact factor >10. The CPMPSR supported 9 programmatic grants (e.g., P01s and SPOREs). The future plans of the CPMPSR are to add capacity through the hiring of an additional pathologist, providing additional immunohistochemistry services and upgrading existing software. The CPMPSR leverages extensive institutional support, and seeks only 6.5% support from CCSG funds. The Comparative Pathology and Mouse Phenotyping Shared Resource is part of the Diagnostics Grouping.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819
Schuh, Elizabeth M; Portela, Roberta; Gardner, Heather L et al. (2017) Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res 13:294
Kumar, Bhavna; Yadav, Arti; Brown, Nicole V et al. (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget 8:14847-14859
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954
Pearlman, Rachel; Frankel, Wendy L; Swanson, Benjamin et al. (2017) Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 3:464-471
Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427
Teng, Kun-Yu; Han, Jianfeng; Zhang, Xiaoli et al. (2017) Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 16:312-322
Russell, Luke; Bolyard, Chelsea; Banasavadi-Siddegowda, Yeshavanth et al. (2017) Sex as a biological variable in response to temozolomide. Neuro Oncol 19:873-874
Terrazas, Cesar; de Dios Ruiz-Rosado, Juan; Amici, Stephanie A et al. (2017) Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 7:40814
Saporito, Donika; Brock, Pamela; Hampel, Heather et al. (2017) Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer :

Showing the most recent 10 out of 2211 publications